Nurix Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
02 Janvier 2024 - 10:01PM
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage
biopharmaceutical company developing targeted protein modulation
drugs designed to treat patients with hematologic malignancies and
solid tumors, today announced that Arthur T. Sands, M.D., Ph.D.,
president and chief executive officer of Nurix, will present an
overview of Nurix’s achievements in 2023 and major goals for 2024
at the 42nd Annual J.P. Morgan Healthcare Conference on Monday,
January 8, 2024, at 3:00 p.m. PT.
The presentation will be webcast live and may be accessed via a
link in the Investors section of the Nurix website under Events and
Presentations. The archived webcast will be available on the Nurix
website for 30 days after the event.
About Nurix Nurix Therapeutics is a clinical
stage biopharmaceutical company focused on the discovery,
development and commercialization of innovative medicines based on
the modulation of cellular protein levels as a novel treatment
approach for cancer and other challenging diseases. Leveraging
extensive expertise in E3 ligases together with proprietary
DNA-encoded libraries, Nurix has built DELigase, an integrated
discovery platform, to identify and advance novel drug candidates
targeting E3 ligases, a broad class of enzymes that can modulate
proteins within the cell. Nurix’s drug discovery approach is to
either harness or inhibit the natural function of E3 ligases within
the ubiquitin-proteasome system to selectively decrease or increase
cellular protein levels. Nurix’s wholly owned, clinical stage
pipeline includes targeted protein degraders of Bruton’s tyrosine
kinase, a B-cell signaling protein, and inhibitors of Casitas
B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates
activation of multiple immune cell types including T cell and NK
cells. Nurix is headquartered in San Francisco, California. For
additional information visit http://www.nurixtx.com.
Contacts:
InvestorsSilinda NeouNurix
Therapeuticsir@nurixtx.com
Elizabeth Wolffe, Ph.D.Wheelhouse Life Science
Advisorslwolffe@wheelhouselsa.com
MediaAljanae ReynoldsWheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
Nurix Therapeutics (NASDAQ:NRIX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Nurix Therapeutics (NASDAQ:NRIX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024